{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:37:27Z","timestamp":1785818247235,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T00:00:00Z","timestamp":1469664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We assessed 1-year outcomes in patients with atrial fibrillation enrolled in the EurObservational Research Programme AF General Pilot Registry (EORP-AF), in relation to kidney function, as assessed by glomerular filtration rate (eGFR). In a cohort of 2398 patients (median age 69 years; 61% male), eGFR (ml\/min\/1.73\u2009m<jats:sup>2<\/jats:sup>) calculated using the CKD-EPI formula was \u226580 in 35.1%, 50\u201379 in 47.2%, 30\u201349 in 13.9% and &lt;30 in 3.7% of patients. In a logistic regression analysis, eGFR category was an independent predictor of stroke\/TIA or death, with elevated odds ratios associated with severe to mild renal impairment, ie. eGFR\u2009&lt;\u200930\u2009ml\/min\/1.73\u2009m<jats:sup>2<\/jats:sup> [OR 3.641, 95% CI 1.572\u20138.433, p\u2009&lt;\u20090.0001], 30\u201349\u2009ml\/min\/1.73\u2009m<jats:sup>2<\/jats:sup> [OR 3.303, 95% CI 1.740\u20136.270, p\u2009=\u20090.0026] or 50\u201379\u2009ml\/min\/1.73\u2009m2 [OR 2.094, 95% CI 1.194\u20133.672, p\u2009=\u20090.0003]. The discriminant capability for the risk of death was tested among various eGFR calculation algorithms: the best was the Cockcroft-Gault equation adjusted for BSA, followed by Cockcroft-Gault equation, and CKD-EPI equation, while the worst was the MDRD equation. In conclusion in this prospective observational registry, renal function was a major determinant of adverse outcomes at 1 year, and even mild or moderate renal impairments were associated with an increased risk of stroke\/TIA\/death.<\/jats:p>","DOI":"10.1038\/srep30271","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T12:10:39Z","timestamp":1469707839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Glomerular filtration rate in patients with atrial fibrillation and 1-year outcomes"],"prefix":"10.1038","volume":"6","author":[{"given":"Giuseppe","family":"Boriani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Laroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Diemberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mircea Ioachim","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Hvilsted","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucian","family":"Petrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry J. G. M.","family":"Crijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Tavazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y. H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"BFsrep30271_CR1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1093\/eurheartj\/ehi651","volume":"27","author":"G Boriani","year":"2006","unstructured":"Boriani, G., Diemberger, I., Martignani, C., Biffi, M. & Branzi, A. The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems. Eur Heart J. 27, 893\u2013894 (2006).","journal-title":"Eur Heart J."},{"key":"BFsrep30271_CR2","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/europace\/euv202","volume":"17","author":"G Boriani","year":"2015","unstructured":"Boriani, G. et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace. 17, 1169\u20131196 (2015).","journal-title":"Europace."},{"key":"BFsrep30271_CR3","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1093\/eurheartj\/ehs435","volume":"34","author":"GY Lip","year":"2013","unstructured":"Lip, G. Y. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J. 34, 1041\u20131049 (2013).","journal-title":"Eur Heart J."},{"key":"BFsrep30271_CR4","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1001\/jama.2015.4369","volume":"313","author":"GYH Lip","year":"2015","unstructured":"Lip, G. Y. H. & Lane, D. A. Stroke Prevention in Atrial Fibrillation: A Systematic Review. JAMA. 313, 1950\u20131962 (2015).","journal-title":"JAMA."},{"key":"BFsrep30271_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1105594","volume":"367","author":"JB Olesen","year":"2012","unstructured":"Olesen, J. B. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med 367, 625\u2013635 (2012).","journal-title":"N Engl J Med"},{"key":"BFsrep30271_CR6","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","volume":"35","author":"R De Caterina","year":"2014","unstructured":"De Caterina, R. & Camm, A. J. What is \u2018valvular\u2019 atrial fibrillation? A reappraisal. Eur Heart J. 35, 3328\u20133335 (2014).","journal-title":"Eur Heart J."},{"key":"BFsrep30271_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2459\/JCM.0000000000000236","volume":"16","author":"G Boriani","year":"2015","unstructured":"Boriani, G. et al. Non-valvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants. J Cardiovasc Med (Hagerstown). 16, 491\u2013496 (2015).","journal-title":"J Cardiovasc Med (Hagerstown)."},{"key":"BFsrep30271_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/europace\/euv309","volume":"17","author":"H Heidbuchel","year":"2015","unstructured":"Heidbuchel, H. et al. Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 17, 1467\u20131507 (2015).","journal-title":"Europace."},{"key":"BFsrep30271_CR9","unstructured":"Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international. 3 (Suppl): 1\u2013150 (2013)."},{"key":"BFsrep30271_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/europace\/eut373","volume":"16","author":"GY Lip","year":"2014","unstructured":"Lip, G. Y. et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 16, 308\u2013319 (2014).","journal-title":"Europace."},{"key":"BFsrep30271_CR11","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.amjmed.2013.12.022","volume":"127","author":"GY Lip","year":"2014","unstructured":"Lip, G. Y. et al. \u2018Real-world\u2019 antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey. Am J Med. 127, 519\u2013529 (2014).","journal-title":"Am J Med."},{"key":"BFsrep30271_CR12","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1093\/eurheartj\/ehu374","volume":"35","author":"GY Lip","year":"2014","unstructured":"Lip, G. Y. et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J. 35, 3365\u20133376 (2014).","journal-title":"Eur Heart J."},{"key":"BFsrep30271_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1093\/europace\/euu155","volume":"17","author":"GY Lip","year":"2015","unstructured":"Lip, G. Y. et al. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. Europace. 17, 24\u201331 (2015).","journal-title":"Europace."},{"key":"BFsrep30271_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/europace\/euu201","volume":"17","author":"GY Lip","year":"2015","unstructured":"Lip, G. Y. et al. Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace. 17, 194\u2013206 (2015).","journal-title":"Europace."},{"key":"BFsrep30271_CR15","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.amjmed.2014.11.026","volume":"128","author":"G Boriani","year":"2015","unstructured":"Boriani, G. et al. Asymptomatic atrial fibrillation: clinical correlates, management and outcomes in the EORP-AF Pilot General Registry. Am J Med. 128, 509\u2013518 (2015).","journal-title":"Am J Med."},{"key":"BFsrep30271_CR16","first-page":"360","volume":"37","author":"AJ Viera","year":"2005","unstructured":"Viera, A. J. & Garrett, J. M. Understanding interobserver agreement: the kappa statistic. Fam Med. 37, 360\u2013363 (2005).","journal-title":"Fam Med."},{"key":"BFsrep30271_CR17","doi-asserted-by":"crossref","unstructured":"Delong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two ro more correlated receiver operating characteristic curves: A nonparametric approach Biometrics. 44, 837\u2013845 (2008).","DOI":"10.2307\/2531595"},{"key":"BFsrep30271_CR18","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1161\/CIRCULATIONAHA.112.000491","volume":"128","author":"E Marijon","year":"2013","unstructured":"Marijon, E. et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 128, 2192\u20132201 (2013).","journal-title":"Circulation."},{"key":"BFsrep30271_CR19","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1093\/eurheartj\/eht031","volume":"34","author":"G Boriani","year":"2013","unstructured":"Boriani, G. et al. Health technology assessment in interventional electrophysiology and device therapy: a position paper of the European Heart Rhythm Association. Eur Heart J. 34, 1869\u20131874 (2013).","journal-title":"Eur Heart J."},{"key":"BFsrep30271_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1161\/CIRCULATIONAHA.108.816082","volume":"119","author":"AS Go","year":"2009","unstructured":"Go, A. S. et al. Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation. 119, 1363\u20131369 (2009).","journal-title":"Circulation."},{"key":"BFsrep30271_CR21","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1378\/chest.13-2103","volume":"145","author":"A Banerjee","year":"2014","unstructured":"Banerjee, A. et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest. 145, 1370\u20131382 (2014).","journal-title":"Chest."},{"key":"BFsrep30271_CR22","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2014.03.022","volume":"64","author":"CT January","year":"2014","unstructured":"January, C. T. et al. 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 64, e1\u201376 (2014).","journal-title":"J Am Coll Cardiol."},{"key":"BFsrep30271_CR23","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","volume":"130","author":"AS Levey","year":"1999","unstructured":"Levey, A. S. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modifi-cation of Diet in Renal Disease Study Group. Ann Intern Med 130, 461\u2013470 (1999).","journal-title":"Ann Intern Med"},{"key":"BFsrep30271_CR24","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 150, 604\u2013612 (2009).","journal-title":"Ann Intern Med"},{"key":"BFsrep30271_CR25","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1136\/heartjnl-2014-306013","volume":"101","author":"J Kornej","year":"2015","unstructured":"Kornej, J. et al. Changes in renal function after catheter ablation of atrial fibrillation are associated with CHADS2 and CHA2DS2-VASc scores and arrhythmia recurrences. Heart. 101, 126\u2013131 (2015).","journal-title":"Heart."},{"key":"BFsrep30271_CR26","doi-asserted-by":"publisher","first-page":"785","DOI":"10.7326\/0003-4819-156-11-201203200-00391","volume":"156","author":"A Earley","year":"2012","unstructured":"Earley, A., Miskulin, D., Lamb, E. J., Levey, A. S. & Uhlig, K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 156, 785\u2013795 (2012).","journal-title":"Ann Intern Med"},{"key":"BFsrep30271_CR27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft, D. W. & Gault, M. H. Prediction of creatinine clearance from serum creatinine. Nephron 16, 31\u201341 (1976).","journal-title":"Nephron"},{"key":"BFsrep30271_CR28","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2215\/CJN.06870909","volume":"5","author":"WM Michels","year":"2010","unstructured":"Michels, W. M. et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol 5, 1003\u20131009 (2010).","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFsrep30271_CR29","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.recesp.2014.06.027","volume":"68","author":"S Manzano-Fern\u00e1ndez","year":"2015","unstructured":"Manzano-Fern\u00e1ndez, S. et al. Comparison of estimated glomerular filtration rate equations for dosing new oral anticoagulants in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed). 68, 497\u2013504 (2015).","journal-title":"Rev Esp Cardiol"},{"key":"BFsrep30271_CR30","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/j.jacc.2011.11.066","volume":"59","author":"E Zamora","year":"2012","unstructured":"Zamora, E. et al. Estimated glomerular filtration rate and prognosis in heart failure: value of the Modification of Diet in Renal Disease Study, Chronic Kidney Disease Epidemiology collaboration, and Cockroft-Gault formulas. J Am Coll Cardiol. 59, 1709\u20131715 (2012).","journal-title":"J Am Coll Cardiol."}],"updated-by":[{"DOI":"10.1038\/srep42379","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep30271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30271","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep30271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T05:32:52Z","timestamp":1672896772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep30271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,7,29]]}},"alternative-id":["BFsrep30271"],"URL":"https:\/\/doi.org\/10.1038\/srep30271","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]},"assertion":[{"value":"11 February 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 February 2017","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction has been published and is appended to both the HTML and PDF versions of this paper. The error has not been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Boriani\u2014received small speaker\u2019s fees from Boehringer, Medtronic Inc and Boston Scientific. L.H.Rasmussen\u2014speaker bureaus for Bayer, BMS\/Pfizer, Janssen Pharmaceuticals, Takeda, Roche Diagnostics, and Boehringer Ingelheim. L.Tavazzi\u2014consultant and Speakers bureau member for Servier; Committee Member for Servier, Medtronic, St Jude Medical, CVIE Therapeutics, Boston Scientific, Vifor Pharma, Cardiorentis. G.Y.H.Lip\u2014consultant for Bayer, Medtronic, Sanofi, BMS\/Pfizer, Daiichi-Sankyo, and Boehringer Ingelheim, and has been a speaker for Bayer, BMS\/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo and Medtronic. Other authors\u2014none declared in relation to this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"30271"}}